Publication
Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management.
Roberto Mina, Evangelos Terpos, Lorenzo Cani, Ajay Nooka, Suzanne Trudel, Peeter Voorhees, Hira Mian, Binod Dhakal, Saad Usmani, Joshua Richter, Rakesh Popat, Maria Victoria Mateos, Sagar Lonial
- Source
- PubMed
- Retrieved
- Sep 16, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260916-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Belantamab mafodotin (belamaf) is an antibody-drug conjugate targeting B-cell maturation antigen on plasma cells. The phase III DREAMM-7 and DREAMM-8 trials, in which belamaf was combined with bortezomib-dexamethasone or pomalidomide-dexamethasone, respectively, showed significantly higher overall…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMultiple Myelomadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available